NCT00583518已完成4 期
Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Nycomed
- 入组人数
- 129
- 试验地点
- 2
- 主要终点
- Correlation coefficient between the percentage of increase in Bone Mineral Density (BMD) obtained by DXA in the lumbar spine and in Trabecular Fragment Length (TFL) obtained by ImaTx in digitised radiographs of lumbar spine from baseline to EOT
研究概览
简要总结
The primary objective of the study is to explore the relationship between a new image technology (ImaTx), that analyzes the trabecular structure of the bone using digitized radiographs and the bone mineral density (BMD) measured by Dual X-ray Absorptiometry (DXA) in the lumbar spine of postmenopausal (PM) women with osteoporosis (OP) after treatment with PTH (1-84).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Has the subject given informed consent according to local requirements before any trial-related activities? A trial-related activity is any procedure that would not have been performed during the routine management of the subject.
- •Is the subject a female?
- •Is the subject 65 years old or above?
- •Is the subject postmenopausal (more than 5 years), in the judgement of the investigator?
- •Does the subject have primary osteoporosis, with a lumbar spine T score ≤ -3.0 SD, or a lumbar spine T-score ≤ -2.5 SD and previous fragility fracture[1], with a minimum of two evaluable lumbar vertebrae?
- •Does the subject have a life expectancy of > 2 years?
- •Does the subject have a clinical indication to receive PTH(1-84) and is able to self-inject (or to have PTH(1-84) injection by a helper)?
- •All inclusion criteria must be answered "yes" for a subject to participate in the trial.
- •[1] Definition of fragility fracture in the scope of the study: Bone fractures that occur as a result of a fall from standing height or less. That is, fractures resulting from mechanical forces that would not ordinarily cause fractures in a healthy person.
排除标准
- •Is the patient currently taking any of the following treatments: bisphosphonates, selective estrogen receptor modulators or hormone replacement therapy (if the patient discontinues any of these treatments at the screening visit, the question can be answered NO and the patient can be included)?
- •Has the subject received, during her lifetime, strontium, fluoride or calcitonin > 3 months in total?
- •Has the subject ever been treated with teriparatide or PTH(1-84)?
- •Is the subject taking any other medication known to affect bone metabolism in the opinion of the investigator?
- •Has the subject ever received radiation therapy to the skeleton?
- •Has the subject ever been treated for a bone malignant disease?
- •Is the subject suffering from any known clinically significant diseases affecting calcium metabolism, including metabolic bone diseases such as hyperparathyroidism, Paget's disease, osteogenesis imperfecta, or osteomalacia?
- •Does the subject have any known history of hypersensitivity to parathyroid hormone or any of the excipients in the drug?
- •Does the subject have an elevated serum calcium (total serum calcium value >10.2 mg/dl) after at least 14 days of a 1000 mg calcium and 800 IU vitamin D3 supplementation?
- •Does the subject have a clinically significant elevation of serum alkaline phosphatase judged by the investigator?
- •Does the subject have an impaired kidney function with creatinine clearance <30ml/min (indirect measurement by serum creatinine)?
- •Does the subject have a severe hepatic impairment, defined as > 9 Child-Pugh score?
- •Has the subject participated in a clinical trial with an Investigational Medicinal Product (IMP) during the last 30 days?
- •Does the subject have a bilateral hip replacement?
- •All exclusion criteria must be answered "no" for a subject to participate in the trial.
结局指标
主要结局
Correlation coefficient between the percentage of increase in Bone Mineral Density (BMD) obtained by DXA in the lumbar spine and in Trabecular Fragment Length (TFL) obtained by ImaTx in digitised radiographs of lumbar spine from baseline to EOT
时间窗: 72 weeks
次要结局
- BMD obtained by DXA in the lumbar spine (DXA SPI BMD). Two measurements will be determined: Mean value (g/cm2) and percentage of increase at EOT versus baseline (%).(72 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
1 期
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabMetastatic MelanomaNCT04955262Nektar Therapeutics
已完成
2 期
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of ChemotherapyNon-seminomatous Germ Cell TumorsMetastasisNCT02317393Centre Francois Baclesse16
招募中
不适用
Neuromodulation for SchizophreniaSchizophreniaNCT05580211Scion NeuroStim34
进行中（未招募）
不适用
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's DiseaseMild Cognitive ImpairmentAlzheimer DiseaseDementiaNCT05579236University Hospital Southampton NHS Foundation Trust400
已完成
不适用
Imaging Methods for the Diagnosis of Non-melanoma Skin Cancer and Its PrecursorsNon-melanoma Skin CancerNCT05842421Technische Universität Dresden250